Polar Capital Holdings Plc Has $40.28 Million Stake in Stoke Therapeutics, Inc. $STOK

Polar Capital Holdings Plc lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 4.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,269,131 shares of the company’s stock after selling 54,339 shares during the quarter. Polar Capital Holdings Plc’s holdings in Stoke Therapeutics were worth $40,282,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Morgan Stanley increased its holdings in shares of Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after purchasing an additional 9,108 shares during the period. Vanguard Group Inc. boosted its stake in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares during the period. State Street Corp grew its position in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock worth $11,053,000 after buying an additional 293,072 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Stoke Therapeutics by 36.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,227,723 shares of the company’s stock worth $38,968,000 after acquiring an additional 327,451 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, March 20th. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Wedbush boosted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.83.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $29.15 on Wednesday. The business has a fifty day moving average price of $32.12 and a two-hundred day moving average price of $32.36. The stock has a market capitalization of $1.82 billion, a PE ratio of -10.37 and a beta of 1.17. Stoke Therapeutics, Inc. has a fifty-two week low of $11.17 and a fifty-two week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The company had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. As a group, sell-side analysts expect that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by corporate insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.